<DOC>
	<DOCNO>NCT00746967</DOCNO>
	<brief_summary>The purpose study evaluate safety toleration oral sildenafil administer required woman Female Sexual Arousal Disorder ( FSAD ) successfully complete one follow Pfizer-sponsored , 12-week , double-blinded clinical trial : A1481082 A1481123 . Addition 52-week open-label extension increase total duration sildenafil exposure 64 week . Sustained efficacy also evaluate 3 6 month open-label therapy .</brief_summary>
	<brief_title>An Open-Label , Extension Study Evaluating Safety , Toleration , Efficacy Sildenafil Women With Sexual Arousal Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Included subject complete Pfizer study A1481082 A1481123 without major protocol violation treatmentrelated adverse event resolve prior crossover openlabel study . For subject receive hormone replacement therapy and/or selective serotonin reuptake inhibitor treatment , dosage must stable start extension study remain stable throughout . Subjects continue maintain stable sexual relationship throughout study . Excluded subject experience either treatmentrelated serious adverse event significant treatmentrelated laboratory abnormality previous study , subject misuse study medication and/or fail adequately account study medication previous study , noncompliant visit . Also excluded subject currently prescribe and/or take nitrate nitric oxide donor form ( oral , sublingual , buccal , transdermal , inhalational aerosol ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>